Nemolizumab efficacy in prurigo nodularis: onset of action on itch and sleep disturbances.

ABSTRACT:

Background

Patients with prurigo nodularis (PN) have multiple itchy nodules, impaired quality of life and sleep deprivation. Prurigo nodularis patients have a high burden of disease, primarily due to the intensity of the itch. It is reasonable to expect that rapid relief of itch - and associated improvement of sleep - are highly valued clinical outcomes for patients. Nemolizumab is an IL-31A-receptor inhibitor that modulates the neuroimmune response with reported positive efficacy and safety data in a phase 2 study of PN.

Objectives

To evaluate the onset of action of nemolizumab on itch and sleep disturbances.

Methods

Post hoc analysis of a phase 2 trial of nemolizumab 0.5 mg/kg SC vs. placebo in patients (n = 70) with moderate-to-severe PN (≥20 nodules) and severe pr

SUBMITTER: Stander S 

PROVIDER: S-EPMC9796585 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature